

DAFTAR PUSTAKA

1. Husniawati N. Faktor-Faktor Yang Berhubungan Dengan Kejadian Ulkus Kaki Diabetes Mellitus Di Klinik Diabetes Mellitus Tahun 2015. *Jurnal Ilmu Kesehatan*. 2015;7(2):138–43.
2. Auliana A, Yunir E, Putranto R, Nugroho P. Pengaruh Depresi Terhadap Perbaikan Infeksi Ulkus Kaki Diabetik. *Jurnal Penyakit Dalam Indonesia*. 2015;2(4):212–6.
3. Decroli E, Karimi J, Manaf A, S S. Profil Ulkus Diabetik Pada Penderita Rawat Inap di Bagian Penyakit Dalam RSUP Dr. M. Djamil Padang. *Majalah Kedokteran Indonesia*. 2008;
4. Agistia N, Mukhtar H, Nasif H. Efektifitas Antibiotik pada Pasien Ulkus Kaki Diabetik. *J Sains Farm Klin* [Internet]. 2017;4(1):43. Available from: <http://jsfkonline.org/index.php/jsfk/article/view/144>
5. Ibnu RSI, Padang S, Roza RL, Afriant R, Edward Z. Artikel Penelitian Faktor Risiko Terjadinya Ulkus Diabetikum pada Pasien Diabetes Mellitus yang Dirawat Jalan dan Inap di RSUP Dr . M . 4(1):243–8.
6. Lipsky B, Berendt A, Cornia P, Pile J, Peters E, Armstrong D, *et al*. Highlights from 2012 Infectious Diseases Society of America Clinical Practice Guidelines for The Diagnosis and Treatment of Diabetic Foot Infections. *Infect Dis Clinical Practice*. 2013;21(1):43–5.
7. Diabetes AA. Standards of Medical Care in Diabetes-2018. In: *Diabetes Care*. 2018. p. 2045–7.
8. Dharma S. *Buku Ajar Praktis Patofisiologi Farmakologi & Farmakoterapi*. Universitas Andalas, Padang; 2017.
9. Kartika RW. Pengelolaan Gangren Kaki Diabetik. *CDK-248*. 2017;44(1).
10. Fitria E, Nur A, Marissa N, Nur Ramadhan. Karakteristik Ulkus Diabetikum pada Penderita Diabetes Mellitus di RSUD dr. Zainal Abidin dan RSUD Meuraxa Banda Aceh. (Eka Fitria [Internet]. 2017;153–60. Available from: <https://media.neliti.com/media/publications/197276-ID-karakteristik-ulkus-diabetikum-pada-pend.pdf>
11. *Guidelines Clinical Practice. Management of Diabetic Foot*. 2018;
12. Chauchard MC, Cousty-Pech F, Martini J, Hanaire-Broutin H. [Diabetic foot]. *Rev Prat* [Internet]. 2001;51(16):1788–92. Available from: <http://www.ncbi.nlm.nih.gov/pubmed/11795123>

13. Frykberg RG, Armstrong DG, Giurini J, Edwards A, Kravette M, Kravitz S, *et al.* Diabetic Foot Disorders: A Clinical Practice Guideline. *Journal Foot Ankle Surgery*. 2006;45(5):S1–66.
14. Omar NS, El-Nahas MR, Gray J. Novel Antibiotics for The Management of Diabetic Foot Infections. *International Journal Antimicrobial Agents*. 2008;31(5):411–9.
15. Kwon KT, Armstrong DG. Microbiology and Antimicrobial Therapy for Diabetic Foot Infections. *Infect Chemother*. 2018;50(1):11–20.
16. Mavrogenis AF, Megaloikonomos PD, Antoniadou T, Igoumenou VG, Panagopoulos GN, Dimopoulos L, *et al.* Current Concepts for The Evaluation and Management of Diabetic Foot Ulcers. *EFORT Open Rev* [Internet]. 2018;3(9):513–25. Available from: <https://online.boneandjoint.org.uk/doi/10.1302/2058-5241.3.180010>
17. Nugroho AE. *Farmakologi Obat-Obat Penting dalam Pembelajaran Ilmu Farmasi dan Dunia Kesehatan*. Pustaka Belajar; 2012.
18. Day C. Foot Guide. *Journal Diabetes Vascular Disease*. 2006;6(3):139–40.
19. Clayton W, Elasy TA. A Review of The Pathophysiology, Classification, and Treatment of Foot Ulcers in Diabetic Patients. 2009;27(2):52–8.
20. Edmons M, EVM F, LF S. *A Practical Manual of Diabetic Foot Care*. London: Blackwell Publishing; 2006.
21. Bergman BS, Pharm D, Id B, Shah PJ, Pharm D. *Diabetic Foot Infections*. 2016;2007(Cdc 2014).
22. G. KB, Masters B, J. Trevor A. *Basic & Clinical Pharmacology*. 12th edition. San Fransisco: Mc-Graw Hill; 2012.
23. Britz M., Wilkinson R. Isolation and Properties of Metronidazole-resistant Mutants of *Bacteroides fragilis*. *Antimicrobial Agents Chemother*. 1979;16:19–27.
24. Sindar P, Britz M., Wilkinson R. Isolation and Properties of Metronidazole-resistant Mutants of *Clostridium perfringens*. *Journal Med Microbiology*. 1982;15:503–9.
25. Cerkasovova A, Cerkasov J, Kulda J. Metabolic Differences Between Metronidazole Resistant and Susceptible Strains of *Tritrichomonas foetus*. *Molecular Biochem Parasitology*. 1984;11:105–18.
26. Yabuuchi E OA. *Achromobacter xylosoxidans sp.* from Human Ear Discharge. *JPN Journal Microbiology*. 1971;15(477):81.

27. Hoban, D.J., Nicolle, L.E., Hawser, S., Bouchillon, S., Badal R. Antimicrobial Susceptibility of Global Inpatient Urinary Tract Isolates of *Escherichia coli*: Results from The Study for Monitoring Antimicrobial Resistance Trends (SMART) Program: 2009–2010. *Diagn Microbiology Infectious Disease*. 2011;70:507–11.
28. Satari HI, Amir I. Gambaran Infeksi *Acinetobacter baumannii* dan Pola Sensitivitasnya Terhadap Antibiotik. 2014;16(1):35–40.
29. Joly-guillou ML, Wolff M, Farinotti R, Bryskier A, Carbon C. JAC In vivo Activity of Levofloxacin alone or in Combination with Imipenem or Amikacin in a Mouse Model of *Acinetobacter baumannii* Pneumonia. 2000;827–30.
30. Sumita Y, Fakasawa M. Potent Activity of Meropenem Against *Escherichia coli* Arising from Its Simultaneous Binding to Penicillin-binding Proteins 2 and 3 Meropenem is a Potent Carbapenem Antibiotic with a Broad Spectrum of Activity. 1995;53–64.
31. Marsot, A.; Guilhaumou, R.; Riff, C.; Blin O. Amikacin in Critically Ill Patients: A Review of Population Pharmacokinetic Studies. *Clinical Pharmacokinetic*. 2017;56:127–138.
32. Kondo, J.; Francois, B.; Russell, R.J.; Murray, J.B.; Westhof E. Crystal Structure of The Bacterial Ribosomal Decoding Site Complexed with Amikacin Containing the γ -amino- α -hydroxybutyryl (haba) Group. *Biochimie*. 2006;88:1027–1031.
33. Russell, R.J.; Murray, J.B.; Lentzen, G.; Haddad, J.; Mobashery S. The Complex of a Designer Antibiotic with a Model Aminoacyl Site of The 30S Ribosomal Subunit Revealed by X-ray Crystallography. *JAm Chem Soc*. 2003;125:3410–3411.
34. Jenny M, Kingsbury J. iMedPub Journals Properties and Prevention : A Review of *Pseudomonas aeruginosa*. 2018;1–8.
35. Aldred KJ, Kerns RJ ON. Mechanism of Quinolone Action and Resistance. *Biochemistry*. 2014;53:1565–1574.
36. A. B. A. Management of Diabetic Foot Infections with Appropriate Use of Antimicrobial Therapy. *Clin Res Foot Ankle*. 2014;3(10):1–10.
37. Junguera LC. *Basic Histology*. Edisi 8. New York: Mc-Graw Hill; 1977.
38. Hamzah A, Anwar Y, Sigit E. Evaluation of Drug Related Problems in The Treatment of Head Injury in Hospital TNI-AL Dr. Mintohardjo. *International Journal Pharm Teach Practice*. 2015;6(03):2162–6.

39. B. W, J. D, L. T. Pharmacotherapy Handbook. 7th edition. New York: The McGraw-Hill Companies. Inc; 2009.
40. Misnadiarly. Diabetes Mellitus Gangren, Ulcer, Infeksi. Jakarta: Penerbit Populer Obor; 2006.
41. Cns KA, Masters J. Temperature Measurement for Critically Ill Adults A Clinical Practice Guideline.

